Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab

Multiple Sclerosis Clinical Trial

— PROTYS  

Official title:

A Prospective, Multicenter, Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Patients Treated With Natalizumab

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02386566
• Other study ID #: CHE-TYS-12-10341
• Status: Completed
• Start date: March 20, 2015
• Est. completion date: January 28, 2018

Study information

• Verified date: September 2018
• Source: Biogen
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The primary objective of the study is to determine the association between prospectively measured disability (Expanded Disability Status Scale [EDSS]) with quality of life (Multiple Sclerosis International Quality of Life Questionnaire [MusiQoL]) at 3-month intervals up to 1 year in a real life setting of multiple sclerosis (MS) patients treated with natalizumab. The secondary objectives of this study are as follows: To evaluate the cumulative probability of sustained EDSS changes at 1 year following natalizumab treatment initiation; To evaluate the association between disability (EDSS), fatigue (Fatigue Scale of Motor and Cognitive Function [FSMC]), sexual dysfunction (Multiple Sclerosis Intimacy and Sexuality Questionnaire-19 [MSISQ-19]), depression (Beck Depression Inventory-Fast Screen [BDI-FS]) and neurocognitive function (Symbol Digit Modalities Test [SDMT]) with EuroQol-5D Questionnaire (EQ-5D) at 3 to 6-months intervals up to 1 year after initiation of natalizumab treatment; To assess the relationship between clinical disease-free status (no EDSS increase of 1.0 and no relapse) and MusiQoL at 1 year following natalizumab treatment initiation; To record the number of clinical relapses and relapses requiring steroid treatment at 3-months intervals up to 1 year after initiation of natalizumab treatment; To describe changes in work impairment (Work Productivity and Activity Impairment in MS [WPAI-MS]) at 3-months intervals up to 1 year after initiation of natalizumab treatment; To describe any change in the percentage of disability pension and occupation after 1 year of natalizumab treatment; To record the incidence and number of Serious Adverse Events (SAE) and Suspected Unexpected Serious Adverse Reactions (SUSAR) throughout the study

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: January 28, 2018
• Est. primary completion date: January 28, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Key Inclusion Criteria:

• Subjects that have a confirmed diagnosis of RRMS, as per the 2010 revised McDonald criteria

• Subjects satisfying the therapeutic indication of natalizumab, as described in the local product label and confirmed by the Investigator. (Patients with previous treatment with natalizumab are also considered to be eligible only if the last natalizumab infusion was at least 1 year before the screening visit of this study)

• Decision for a treatment with natalizumab has been made before screening

• Patients with an EDSS score of 2.0-5.5 (both limits inclusive)

Key Exclusion Criteria:

• Patients with a diagnosed co-existing brain pathology other than MS, which in the judgement of the investigator impacts the value of EDSS or QoL.

• Pure spinal manifestation of demyelination

• Diagnosis of primary or secondary progressive MS

• Any change in concomitant medication known to affect cognition or bladder function

• A history of severe depressive disorder and/or suicidality, seizure, drug or alcohol abuse, as assessed by the Investigator

NOTE: Other Protocol Defined Inclusion/ Exclusion Criteria May Apply.

Related Conditions & MeSH terms

• Multiple Sclerosis

Intervention

Drug:
• natalizumab
As described in the treatment arm

Locations

Country	Name	City	State
Switzerland	Research Site	Aarau
Switzerland	Research Site	Basel
Switzerland	Research Site	Bern
Switzerland	Research Site	Lugano
Switzerland	Research site - private practice	Luzern
Switzerland	Research Site	Wohlen
Switzerland	Research Site	Zurich

Sponsors (1)

Lead Sponsor	Collaborator
Biogen

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Compare EDSS change categories with changes in MusiQoL	The EDSS measures disability status on a scale ranging from 0 to 10, with higher scores indicating more disability. Scoring is based on measures of impairment in eight functional systems on examination by a neurologist. The MusiQOL is a multidimensional Health Related Quality of Life (HRQoL) instrument that provides information based on the views and perceptions of the participants.	At 1 year after initiating natalizumab treatment
Secondary	Cumulative probabilities of sustained improvement and progression in neurological disability		At 1 year after initiating natalizumab treatment
Secondary	Compare clinical disease-free status (no sustained EDSS increase of 1.0 and no relapse) with MusiQoL		Up to 1 year after initiating natalizumab treatment
Secondary	Compare EDSS change categories with EQ-5D	The EQ-5D is a two-part instrument that consists of the following administered together: 1) EQ-5D-5L- The descriptive system comprises the same 5 dimensions as the EQ-5D-3L (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension now has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. EQ-VAS describes the respondent's self-rated health on a vertical visual analog scale (VAS).	Up to 1 year after initiating natalizumab treatment
Secondary	Compare FSMC score with EQ-5D	FSMC provides differential quantification and graduation of cognitive and motor fatigue. The total score ranges from 0 to 100 with higher scores indicating more fatigue.	Up to 1 year after initiating natalizumab treatment
Secondary	Compare MSISQ-19 scores with EQ-5D	MSIS-Q is a 19-question survey to assess sexual QoL in MS patients. The scoring is based on a scale ranging from 1 (never interfered with my sexual activity or satisfaction) to 5 (always interfered with my sexual activity or satisfaction).	Up to 1 year after initiating natalizumab treatment
Secondary	Comparison of BDI-FS with EQ-5D	The Beck Depression Inventory (BDI) as measured by the BDI-FS is a 7-item multiple-choice self-report inventory for measuring the severity of depression in MS.	Up to 1 year after initiating natalizumab treatment
Secondary	Compare SDMT scores with EQ-5D	SDMT is a screening test for cognitive impairment. It assesses key neurocognitive functions that underlie many substitution tasks, including attention, visual scanning, and motor speed. SDMT scores are highly correlated to Magnetic Resonance Imaging (MRI) derived measures of disease burden and disability progression in MS patients.	Up to 1 year after initiating natalizumab treatment
Secondary	Rates of clinical relapses and relapses requiring steroid treatment		Up to 1 year after initiating natalizumab treatment
Secondary	Changes in the WPAI questionnaire	The WPAI questionnaire is a validated instrument to measure impairments in work and activities. The WPAI yields four types of scores: 1. Absenteeism (work time missed) 2. Presenteesism (impairment at work / reduced on-the-job effectiveness) 3. Work productivity loss (overall work impairment / absenteeism plus presenteeism) 4. Activity Impairment. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.	Up to 1 year after initiating natalizumab treatment
Secondary	Change in kind and percentage of occupation due to MS		At 1 year after initiating natalizumab treatment
Secondary	Change in the percentage of disability pension		At 1 year after initiating natalizumab treatment
Secondary	Incidence and number of SAEs and SUSARs		Up to 1 year after initiating natalizumab treatment